 PART B: This is the dose-escalation combination therapy portion study of Anti-LAG-3 monoclonal antibody BMS-986016 plus Anti-PD-1nivolumab and Anti-CD137 urelumab plus Anti-PD-1 nivolumab. Patients are assigned to 1 of 2 arms. 